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Original research article—Basic science
Transcriptional Signatures That Define Ulcerative Colitis in 
Remission
Christopher G. Fenton, PhD,* Hagar Taman, MSc,*,† Jon Florholmen, MD, PhD,†,‡ Sveinung W. Sørbye, 
MD, PhD,§ and Ruth H. Paulssen, PhD*,†
Background: This study addresses whether existing specific transcriptional profiles can improve and support the current status of the defi-
nition of ulcerative colitis (UC) remission apart from the existing endoscopic, histologic, and laboratory scoring systems. For that purpose, a 
well-stratified UC patient population in remission was compared to active UC and control patients and was investigated by applying the next-
generation technology RNA-Seq.
Methods: Mucosal biopsies from patients in remission (n = 14), patients with active UC (n = 14), and healthy control patientss (n = 16) under-
went whole-transcriptome RNA-Seq. Principal component analysis, cell deconvolution methods, gene profile enrichment, and pathway enrich-
ment methods were applied to define a specific transcriptional signature of UC in remission.
Results: Analyses revealed specific transcriptional signatures for UC in remission with increased expression of genes involved in O-glycosylation 
(MUC17, MUC3A, MUC5AC, MUC12, SPON1, B3GNT3), ephrin-mediated repulsion of cells (EFNB2E, EFNA3, EPHA10, EPHA1), GAP 
junction trafficking (TUBA1C, TUBA4A, TUBB4B, GJB3, CLTB), and decreased expression of several toll-like receptors (TLR1, TLR3, TLR5, 
TLR6).
Conclusions: This study reveals specific transcriptional signatures for remission. Partial restoration and improvement of homeostasis in the ep-
ithelial mucus layer and revival of immunological functions were observed. A clear role for bacterial gut flora composition can be implied. The 
results can be useful for the development of treatment strategies for UC in remission and may be useful targets for further investigations aiming 
to predict the outcome of UC in the future.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory dis-
order that requires long-term treatment to achieve remission.1 
The inflammation status of UC is usually determined by en-
doscopic, histologic, and laboratory parameters.2 Current 
management programs aim for induction and maintenance 
of clinical remission to prevent disease-related and treatment-
induced complications.3, 4 Different scoring systems for UC 
activity are used to evaluate endoscopic disease activity and 
activity status, but none have yet had all properties fully as-
sessed.5, 6 However, there is no consensus on how to define 
clinical remission as no validated definition exists. The last 
guidelines from the European Colitis and Crohn’s Organization 
included clinical and endoscopic parameters where no mucosal 
lesions should appear (Mayo endoscopic grade 0).7 Despite 
this instruction, in most clinical studies Mayo grade 1 is in-
cluded in the definition of clinical remission.8, 9 It is well known 
that clinical and endoscopic remission as defined above indeed 
may involve persisting microscopic inflammatory activity even 
in the absence of gastrointestinal symptoms.10-13 This activity 
can result in progressive accumulation of bowel damage, such 
as dysmotility, fibrosis, and increased risk of colorectal ne-
oplasm.10, 14-17 There  is a need for standardization of the as-
sessment of remission and validation that gives a prognostic 
value.18 Therefore, an urgent need to characterize the complex 
pathogenic and healing mechanisms in UC still exists. 
It is believed that the elucidation of key inflammatory 
pathways and perturbations involved by integrated clinical 
and genomic analyses should provide insight into the molec-
ular events and pathways that are involved during remission. 
Recently, attempts have been made to describe transcriptional 
doi: 10.1093/ibd/izaa075
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levels in UC remission by using microarrays.19-21 However, 
hybridization-based methods are restricted to predefined 
and often well-annotated species and RNA probe sets. Next-
generation sequencing techniques have no such restrictions, 
which may lead to the discovery of potential new transcripts 
with a meaning for UC in remission. A  transcriptomic study 
using RNA-Seq technology has been recently reported for the 
pediatric UC cohort PROTECT.22, 23
This study is the first to describe the entire transcriptomic 
landscape of adult UC in remission using next-generation 
sequencing technology with a focus on a clearly defined and 
representative group of UC patients in remission.
The establishment of robust and more specific biomarker 
groups and genomic signatures of UC remission may also lead 
to novel therapeutic approaches and is believed to pave the way 
for the development of personalized treatment options for UC 
patients in the future.
METHODS
Patient Material
A standardized sampling method was used to collect 
mucosal biopsies (N = 44) from patients in remission (n = 14), 
newly diagnosed treatment-naïve UC patients with mild to 
moderate disease (n  =  14), and control patients (n  =  16). 
Normal biopsies were taken from an earlier study.24 Patients’ 
UC was diagnosed based upon established clinical endoscopic 
and histological criteria as defined by the European Colitis 
and Crohn’s Organization guidelines. The grade of inflamma-
tion was assessed during colonoscopy using the UC disease 
activity index endoscopic subscore of 3-10 for mild to mod-
erate disease.7 Tumor necrosis factor-alpha mRNA expression 
levels were measured by real-time quantitative polymerase 
chain reaction (qPCR), thereby indicating the grade of UC ac-
tivity.20 Fecal calprotectin was measured in all patients repre-
senting remission and in 8 patients representing active UC with 
the Calprest ELISA kit (Eurospital). A total Geboes score was 
assessed for all biopsies representing remission and for 9 sam-
ples representing active UC.25 Patients in the remission group 
remained in remission for more than 1.5 years after discontinu-
ation of treatment. The samples were taken from an established 
biobank approved by the Norwegian Board of Health. Patient 
characteristics are depicted in Table 1.
RNA Isolation
Total RNA was isolated using the Allprep DNA/
RNA Mini Kit from Qiagen (catalog number 80204) and the 
QIAcube instrument (Qiagen), according to the manufacturer’s 
protocol. The RNA quantity and purity were assessed by using 
the NanoDrop ND-1000 spectrophotometer (ThermoFisher 
Scientific, Wilmington, DE). The Experion Automated 
Electrophoresis System (Bio-Rad, Hercules, CA) and the RNA 
StdSens Analysis Kit (Bio-Rad, catalog number 700–7103) were 
used to evaluate RNA integrity, according to the instruction 
manual. The RNA samples were kept at −70°C until further 
use. All RNA samples used for analyses had a RNA integrity 
number value of between 8.0 and 10.0.
qPCR
The tumor necrosis factor-alpha levels in biopsies were 
measured by using qPCR. The RNA quantity was assessed with 
NanoVue Plus (GE Healthcare, United Kingdom). Synthesis 
of cDNA was performed using the QuantiTect Reverse 
Transcription Kit (Qiagen, catalog number 205314)  and the 
QuantiNova Probe PCR Kit (Qiagen, catalog number 208256). 






UC in Remission 
(n = 14)
Gender (male/female) 11/5 9/5 9/5
Age, y, mean ± SD 52.9 ± 16.9 40.7 ± 13.9 46.5 ± 16.0
Clinical score ± SD 0 7.78 ± 1.52 0.44 ± 1.01*
Endoscopy score mean ± SD 0 1.79 ± 0.43 0
Geboes score (total) n.d. 6.53 ± 2.93 1.07 ± 1.73
TNF-α copies/µg RNA ± SD 3,663 ± 1,973 15,907 ± 9,623 4,645 ± 1,830
Calprotectin (mg/kg) mean ± SD n.d. 587.5 ± 483.8† 53.9 ± 41.1
Extension of disease‡ _ 2/9/3 2/8/4
Medication§ _ _ 14/4/5
aAverage score of 9 patients.
†Average calprotectin levels in 11 patients.
‡Proctitis/left-sided colitis/pancolitis.
§5-aminosalicylic acids/steroids/immunosuppressives.
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Beta-actin was used as the housekeeping gene. For the detec-
tion, a CFX Connect Real Time PCR Detection System (Bio-
Rad) was used. The results were measured in copies/µg. Tissue 
samples with values <7,000 copies/µg RNA were considered 
noninflamed tissues, and values >7,000 copies/µg RNA were 
considered inflamed tissues as depicted in Table 1.26
Library Preparation and Next-Generation 
Sequencing
Whole transcriptome libraries of UC in remission sam-
ples were prepared with the TruSeq Stranded Total RNA LT 
Sample Prep Kit from Illumina (catalog number RS-122–2203). 
The amount of input material was 1  µg of total RNA. The 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) 
and the Agilent DNA 1000 kit (cat number 5067-1504) were 
used to assess RNA library quality, according to the instruc-
tion manual. The RNA libraries comprised fragments with an 
average size of 307 base-pairs. The libraries were normalized 
to 10 nM and subsequently sequenced with the NextSeq 550 
instrument (Illumina) according to the manufacturer’s in-
structions. The average number of uniquely mapped reads per 
sequencing run were 88 million reads per sample.
Data Analysis
Base calling and quality scoring were performed on the 
NextSeq 550 Illumina sequencer. Initial quality checks were 
performed by the NextSeq 550 on-board computer. The STAR-
2.5.2b assembly algorithm and htseq-count were used for down-
stream analysis. Transcripts were aligned to human genome 
assembly GRCH38p.11 (https://www.ncbi.nlm.nih.gov/grc/
human/data), and DESeq2 was used to compile and normalize 
from the individual raw htseq count matrixes. Transcripts with 
an average read count of <30 after DESeq2 normalization were 
excluded from further analysis. The comparisons between the 
UC, remission (R), and normal (N) samples were made using 
the LIMMA package with EBayes to shrink probewise sample 
variances on the DESeq2 normalized data. Only transcripts 
with a log2 fold change >0.5 and a Benjamini-Hochberg ad-
justed P < 0.05 in either UC-R or R-N comparisons were kept 
for further analysis.27
Profile analysis was conducted on the basis of the 
LIMMA results. The profile N < R > UC designated a situation 
where the log2 (R)-log2 (N) fold change was >0.5 and where the 
log2 (R)-log2 (UC) fold change was greater than 0.5. Note that 
the comparison UC-N was not considered in the profiles, as this 
study focused on remission-specific profiles. Both comparisons 
had a P adjusted value <0.05. The profile N > R = UC desig-
nated a situation where log2 (N) > log2 (R) by more than 0.5 
and was significant (adjusted P < 0.05), but the absolute value 
of log2 (UC)-log2 (R) was <abs (0.5) and/or the comparison 
was not significant after the P value adjustment. Profiles in-
cluded were N < R < UC, N > R > UC, N < R > UC, N > R < 
UC, N >R = UC, N < R = UC, N = R > UC, and N = R < UC. 
The gene set overrepresentation test was conducted using the 
enrichPathway algorithm of the R Bioconductor ReactomePA 
package (https://bioconductor.org/packages/release/bioc/html/
ReactomePA.html).28, 29 Genes for each profile were entered into 
the enrichPathway algorithm. Reactome pathways that had a 
significant (adjusted P < 0.05) overrepresentation of genes were 
reported for all profiles.
For the estimation of specific cell populations in patient 
samples, an analysis was performed using the R/Bioconductor 
CellMix manual (http://web.cbio.uct.ac.za/~renaud/CRAN/
web/CellMix/) with the immune response in silico (IRIS) 
weighted marker list characteristic for the different cell types.30 
The epithelial marker cadherin 1, the phosphatidylinositol 
glycan anchor biosynthesis class F, the epithelial cell adhesion 
molecule, the L1 cell adhesion molecule, and the laminin sub-
unit alpha 1 were added to the IRIS marker list and weighted 
strongly to give an estimate of the presence of epithelial frac-
tions in the patient samples.
Heat maps were generated using the pHeatmap R package 
(https://CRAN.R-project.org/package=pheatmap). Only genes 
that were present in one of the reactome overrepresented path-
ways were considered. Heat maps were drawn for genes found 
in an overrepresented reactome pathway for the following pro-
files: N < R < UC, N > R > UC, N < R > UC, and N > R < 
UC. Processed RNA-Seq data were deposited in the National 
Center for Biotechnology Information’s Gene Expression 
Omnibus (https://www.ncbi.nlm.nih.gov/geo/) and are acces-
sible through GEO series accession number GSE128682.
Ethical Considerations
The participants signed an informed and written con-
sent form. The study was approved by the Regional Ethics 
Committee of North Norway and the Norwegian Social 
Science Data Services (REK Nord 2012/1349).
RESULTS
Whole Transcriptional Profile Characterization of 
UC in Remission
The entire transcriptome representing UC in remission 
was established by RNA-Seq, which revealed 13,927 differ-
entially expressed genes (DEGs). Initial principal component 
analysis (PCA) of the entire DESeq2 log-normalized count 
matrix revealed a clear distinction between UC in remission, 
normal, and active UC samples along the first principal com-
ponent with 46.9% and the second principal component with 
9.8% of the total variance (Fig. 1). There were no differences 
in the UC remission sample profile that indicated any gender 
separation. 
To further describe and analyze the transcriptome, the 
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and a log2 fold change > 0.5. The resulting number of signif-
icant DEGs (n = 5,407; Supplementary Data 1) was used for 
further downstream analyses. Fig. 2 depicts the assignment of 
significantly DEGs of normal (green), UC (red), and remission 
(blue) groups to clusters specific for all possible matching pro-
files. The number of genes found in each profile, the number of 
overrepresented reactome pathways, the total number of genes 
found in overrepresented reactome pathways, and a sample box 
plot for 3 genes from each profile are shown. For further inter-
pretation of the results, we describe 4 of the 8 possible profiles, 
indicated by an asterisk in the figure, in detail. They represent 
genes (n = 924) in an intermediate state in remission (N < R 
< UC; N > R > UC) and genes specific for remission (N < R 
> UC; N > R < UC; Fig. 2). The gene clusters of each profile 
underwent reactome pathway enrichment as described in detail 
in “Methods” above, which resulted in a total of 50 annotated 
pathways representative for these profiles (Supplementary Data 
2). Genes in the remaining profiles have been published in pre-
vious research.24 All genes and pathways matching any of the 
profiles can be found in Supplementary Data 1.
A comparison of the data obtained for UC vs normal 
samples with recent published transcriptomic data for the pedi-
atric UC cohort PROTECT showed a strong correlation of 0.94, 
indicating that the datasets are comparable (Supplementary 
Data 3).22 Therefore, we used a remission dataset from the 
PROTECT cohort including a 115 glucocorticoid response 
gene signature and compared it with a remission dataset con-
taining 4 glucocorticoid patient samples from this study. Four 
significantly regulated genes— PHLDA3, DSG3, ABCA12, 
and XKR9—overlapped with the PROTECT glucocorticoid re-
sponse gene signature. In addition, the 4 patient samples with 
glucocorticoid treatment did not separate from the remaining 
remission samples in the PCA (Fig. 1). All the results regarding 
the comparison with the datasets from the PROTECT study are 
shown and summarized in Supplementary Data 3.
Genes in an Intermediate State in UC Remission
The different expression profile patterns with the number 
of genes (n  =  78) including the 3 groups—N, R, and active 
UC for the intermediate state of remission (N < R < UC; N 
> R > UC)—are shown in Fig. 3. Genes that have been pre-
viously shown to have an increased expression in active UC24 
showed increased expresssion but to a lesser extent during re-
mission (n  =  43) (Fig.  3A). Functional annotation (Table  2) 
revealed involvement in neutrophil degranulation (CHI3L1, 
CD55, TCIRG1, OLFM4, UNC13D, LRG1, PLAUR, CXCR1, 
SIRPB1, LPCAT1, TMEM173, FRMPD3, CXCL1) and 
degradation of the extracellular matrix, represented by mem-
bers of the collagen family (COL4A1, COL1A1, COL5A3, 
COL18A1, COL7A1) and several matrix metallopeptidases 
(MMP3, MMP7, MMP10). Further, genes were annotated 
for interleukin signaling (NFKB2, CASP1, SAA1, SOCS1 and 
SOCS3, IGTAX, CCL22, JAK3, IL-1B, LCN2, IL-13RA2) and 
amino acid transport across the plasma membrane, represented 
by several members of the solute carrier family (SLC7A5, 
SLC6A20, SLC7A11, SLC6A14).
Genes that were downregulated in remission to a lesser 
extent than in active UC (n = 35) are depicted in Fig. 3B. Those 
genes could be functionally annotated to pathways (Table  2) 
including biological oxidation, in particular glucuronidation 
(represented by 8 different UDP glucuronosyltransferase family 
members: UGT1A3, UGT1A4, UGT1A 5, UGT1A 6, UGT1A7, 
UGT1A9, UGT1A10, UGT2B7; and 2 cytochrome members: 
CYP27A1 and CYP3A4), solute carrier-mediated transmem-
brane transport and related disorders (represented by 10 solute 
carrier family members), synthesis of bile acids (ABCB11 and 
AMACR), metallothioneins (MT1E, MT1M, MT1F), and 
digestion (GUCA2B and GUCA2A; ALPI). All genes repre-
senting these regulatory profiles can be found in Supplementary 
Data 2.
Genes Specific for UC Remission
Specific expression profile patterns with the number 
of genes (n = 25) including samples for the N, R, and active 
UC (N < R > UC; N > R < UC) groups are shown in Fig. 4. 
Overrepresented pathways of genes (Table 2 and Supplementary 
Data 4)  with increased expression (n  =  20) during remission 
(Fig. 4A) are mainly involved in diseases of glycosylation, rep-
resented by different mucins (MUC5AC, MUC3A, MUC12, 
MUC17), BCAN, SPON1, CSPG4, ADAMTSL5, GNE, 
and B3GNT3. Others could be annotated to GAP junction 
FIGURE 1. PCA showing the difference between active UC (red), UC 
remission (blue), and normal control (green) samples of the top 5,000 
most variable transcripts after DESeq2 rlog normalization. Principal 
component 1 explained 46.9 % of the total variance, and principal com-
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trafficking, such as tubulins (TUBA1C, TUBA4A, TUBB4B), 
CLTB, and GJB3, and in the ephrin-mediated repulsion of cells 
represented by ephrins (EFNA3 and EFNB2), and ephrin type 
A  receptors (EPHA10 and EPHA1) (Fig.  4A). Only 5 genes 
with decreased expression during remission could be enriched 
and annotated to overrepresented pathways for diseases of 
the immune system, in particular diseases associated with the 
toll-like receptor (TLR) signaling cascade including TLR1, 
TLR3, TLR5, and TLR6 and the innate immune signal trans-
duction adaptor MyD88 and interleukin-1 IRAK4 deficiency 
(Fig. 4B). All genes representing these regulatory profiles can 
be found in Supplementary Data 2, and all remaining genes 
after gene set enrichment representing these regulatory profiles 
can be found in Table 2 and Supplementary Data 3.
FIGURE 2. Overview of transcriptional profiles found for UC in remission. Assignment of significantly DEGs of normal (green), UC (red), and re-
mission (blue) groups to clusters specific for all possible matching profiles. Transcripts with a minimum fold change difference of 0.5, an adjusted 
P < 0.05, and a minimum of 30 reads are depicted as # genes. Genes left after pathway enrichment of the different profiles are indicated. The first 
column is a pictorial representation of profiles. The number of genes found in each profile, the number of enriched reactome pathways, the total 
number of genes found in enriched reactome pathways, and sample box plots for 3 genes from each profile are shown. Profiles indicated with (*) are 
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Changes in Fractions of Cell Populations
To estimate specific cell populations in the UC remis-
sion samples compared with the control and active UC tissue 
samples, a cell deconvolution method was applied as described in 
“Methods” above. The deconvolutions were restricted to the fol-
lowing cell types: epithelial cells, monocytes, T-cells, neutrophils, B 
FIGURE 3. Heatmap of genes found in enriched reactome pathway profiles in an intermediate state in remission with indicated profile patterns. 
A, Transcripts with significantly higher expression in remission (R; blue) than in normal (N; green) samples, and transcripts with significantly higher 
expression in UC (red) than in R samples (N < R < UC). B, Transcripts with significantly lower expression in R (blue) than in N (green) samples, and 
transcripts with significantly lower expression in UC (red) than in R samples (N > R > UC). Only transcripts with an absolute fold change >0.5, an ad-
justed P <0.05, and a minimum of 30 reads are depicted. Transcripts were normalized from raw count to log2 values by using DESeq2. Fold change 
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cells/lymphoid cells, and myeloid cells. The results showed a clear 
difference of cell fractions present in the UC remission samples 
when they were compared with the active UC and control samples 
(Fig. 5). The epithelial cell fraction showed intermediate levels in 
the remission samples when they were compared with the normal 
samples and active UC samples. A decrease in fractions of mono-
cytes, T-cells, and B cells/lymphoid cells was observed for the re-
mission samples when they were compared with the active UC 
samples. High fractions of neutrophils observed for active UC 
samples were almost reduced to levels of normal samples in remis-
sion. The fractions of myeloid cells remained unchanged in the re-
mission samples compared with those in the normal samples and 
active UC samples. The results of the deconvolution experiments 
are summarized in Fig. 5.
DISCUSSION
This study provides a unique, comprehensive, and quantita-
tive record of high-resolution gene expression in UC patients in re-
mission using next-generation RNA-Seq technology and provides 
for the first time well-defined transcriptional signature patterns for 
UC in remission obtained by pathway enrichments. A clearly de-
fined patient sample group representing UC in remission was used 
to characterize the representative transcriptional signature of UC 
in remission (Table 1). Initial PCA revealed a quite complex pa-
thology of remission (Fig. 1). Some remission samples clustered 
close to UC and others close to N, demonstrating the variability 
within remission and the challenge of defining remission-specific 
profiles statistically. The assignment of genes to different expression 
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to show that genes found in an intermediate state in remission 
showed reduced but not completely diminished levels of inflamma-
tory signatures when compared with active UC (Fig. 3). This de-
crease may represent the remaining quiescent microscopic disease 
activities during remission as suggested by others.7, 10, 11, 13 Examples 
of considerable downregulated transcripts in remission for previ-
ously reported top upregulated transcripts in active UC are genes 
involved in the degradation of the extracellular matrix, collagen 
degradation, neutrophil degranulation, and signaling by interleu-
kins (Table  2 and Supplementary Data 3). The downregulation 
of the 2 inflammatory bowel disease (IBD) susceptibility genes 
CXCL1 and CXCR1 (Fig. 3) involved in neutrophil degranulation 
was in agreement with almost absent fractions of neutrophils pre-
sent during remission (Fig. 5). These results concurred with a recent 
transcriptomic cohort study including pediatric UC patients.22 Note 
also that a downregulation of transcripts for MMP3, MMP10, 
CH13L1, and CXCL1 during remission has been reported by using 
real-time qPCR.21
The involvement of the microflora and their importance 
in the onset, development, and preservation of UC has been 
implied.31–34 During remission, several genes involved in pa-
tient antibacterial response showed reduced expression, like the 
transporter SLC6A14; the IBD disease marker LCNC2; SAA1, 
which represents an important link between mucosal T-cells 
and microbial communities; and CHI3L1, which lessens bac-
terial adhesion and invasion on/into colonic epithelial cells.35-38 
These observations are in concordance with the results obtained 
by cell deconvolutions, which revealed an improvement of the 
mucus layer in the remission samples when compared with the 
active UC samples by showing decreased fractions of mono-
cytes, T-cells, and B cells/lymphoid cells and enhanced fractions 
of epithelial cells (Fig. 5).
TABLE 2. Reactome-Enriched Pathways and Genes of Indicated UC Remission Profiles for N, UC, and R 
Pathway Gene Symbol
Enriched pathways for N < R < UC (adjusted P < 0.05)  
 Interleukin-4 and interleukin-13 signaling SAA1, MMP3, SOCS1, ITGAX, CCL22, SOCS3, JAK3, 
IL-1B, LCN2, IL-12RA2
 Collagen degradation MMP7, MMP10, COL4A1, COL1A1, COL5A3, COL18A1, 
COL7A1
 Signaling by interleukins PSME2, MAPK11, CXCL1, DUSP4, IL-33
 Extracellular matrix organization ADAMTS9, MADCAM1
 Neutrophil degradation CHI3L3, CD55, TCIRG1, OLFM4, UNC13D, LRG1, PLAUR, 
CXCR1, SIRPB1, LPCAT1, TMEM173, FRMPD3
 Amino acid transport across plasma membrane SLC7A5, SLC6A20, SLC7A11, SLC6A14
 NLRP3 inflammasome PSTPIP1, CASP1, NFKB2
Enriched pathways for N > R > UC (adjusted P < 0.05)  
 Glucuronidation UGT1A10, UGT1A9, UGT1A7, UGT1A6, UGT1A5, UGT1A4, 
UGT2B7, UGT2B7
 Biological oxidations NR1H4, SULT1A2, CYP27A1, SLC26A2, CYP3A4, MAOA
 Solute carrier-mediated transport SLC16A1, SLC3A1, SLC4A4, SLC6A19, SLC22A5, 
SLC26A3, SLC30A10, SLC22A4, SLC36A1, SRI
 Bile acids and bile salt metabolism ABCB11, AMACR
 Abacavir transport and metabolism ABCG2, ABCB1, PCK1
 Metallothioneins (binding metals) MT1E, MT1M, MT1F
 Digestion GUCA2B, GUCA2A, ALPI
Enriched pathways for N < R > UC (adjusted P < 0.05)  
 O-linked glycosylation; O-linked-glycosylation of mucins MUC5AC, MUC3A, MUC12, MUC17, B3GNT3
 O-linked glycosylation SPON1, ADAMTSL5 
 Diseases of glycosylation GNE
 Chondroitin sulfate and dermatan sulfate degradation CSPG4, BCAN, HYAL
 GAP junction trafficking GJB3, TUBA1C, TUBA4A, CLTB, TUBB4B
 EPH-ephrin-mediated repulsion of cells EPHA10, EFNA3, EFNB2, EPHA1
Enriched pathways for N > R < UC (adjusted P < 0.05)  
 TLR signaling cascade; MyD88 deficiency (TRL2/4); 
IRAK4 deficiency (TRL2/4)
TLR1, TLR6, LY96
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However, the main focus of this study was to determine 
more specific transcriptional signatures involved in remission. 
By assigning transcripts to different expression profiles and 
using gene set enrichment methods, we were able to uncover 
transcripts in the remission samples that were differentially 
up- or downregulated as compared to the UC and N sam-
ples (Fig. 4). Surprisingly, enriched pathways for upregulated 
genes in the remission samples were found for pathways such 
as O-glycosylation, GAP junction trafficking, and ephrin-
mediated repulsion of cells (Table 2). It is well acknowledged 
that gastrointestinal O-glycosylated mucins are constituents of 
luminal barrier function and are the first line of host defense 
against invading pathogens.39 The observed increased expres-
sion of the mucin MUC17 and its paralog MUC3A during 
remission (Fig.  4A) may prevent bacterial invasion through 
barrier function by maintaining the integrity of the surface epi-
thelial layer and homeostasis on the mucus surface.39-41 In addi-
tion, MUC17 has been shown to be instrumental in limiting the 
epithelial adhesion and invasion of enteroinvasive Escherichia 
coli.42, 43 In concordance with these results was the observation 
of a partial restoration of the epithelial mucus layer (Fig. 5). 
However, epithelial cell fractions did not reach levels as seen 
in the normal samples, which indicates that mucosal healing in 
UC remission was not fully accomplished. Epithelial cells are 
tightly coupled together through specialized intercellular junc-
tions, including tight junctions and gap junctions,44 and the in-
creased expression of genes annotated for GAP junctions in this 
study (TUBA1C, TUBA4A, TUBB4BCLTB, GNE, GJB3) con-
firm this notion. In addition, the observed increased expression 
of MUC12 may support protection of the epithelial cells in the 
FIGURE 4. Heatmap of specific genes for UC in remission with indicated profile patterns. A, Transcripts with significantly higher expression in re-
mission (R; blue) than in normal (N; green) and UC (red) samples; N < R > UC. B, Transcripts with significantly lower expression in R (blue) than in 
N (green) and UC (red) samples; N > R < UC. Transcripts with a minimum fold change difference of 0.5, an adjusted P < 0.05, and a minimum of 30 








niversity Library of Trom
sø user on 24 April 2020
10
Fenton et al Inflamm Bowel Dis • Volume XX, Number XX, XXXX 2020
mucosa: previous findings showed a significant downregulation 
of MUC12 in the colon and ileum in patients with Crohn di-
sease.45, 46
In addition to the mucins, other genes involved in 
O-linked glycosylation such as B3GNT3 (lymphocyte homing 
and lymphocyte trafficking), SPON1, and ADAMTSL5 
(metalloendopeptidase activity) showed increased expression 
(Fig. 4A). In particular, SPON1 has been shown to regulate 
macrophage microbicidal activity by effectively phagocyt-
izing the bacteria Salmonella typhimurium and E. coli.47-50
An increasing body of evidence suggests that epithelial cells 
also directly exchange information at cell-cell contacts via the 
ephrin family of receptor tyrosine kinases and their membrane-
associated ephrin ligands.51, 52 It has been reported that impaired 
intestinal epithelial barrier and abnormal T-cell responses are ev-
ident during IBD.53, 54 This implies that the observed increased 
levels of EFNB2 in the remission samples may be directly involved 
in the activation of T-cell development,54, 55 in the organization of 
stem cell compartments, and in the ordered migration of epithe-
lial cells along the intestinal villus axis.44 Increased expression of 
EFNB2 has been also found to enhance intestinal wound healing 
in patients with Crohn disease and may play a potential role in the 
EphB/ephrin-B system as a pharmacological target in intestinal in-
flammatory disorders.56, 57
In addition, some of the differentially regulated genes have 
been reported to be associated with the development of colorectal 
cancer such as MUC5AC, the ephrin receptors EPHA10 and 
EPHA10, and OLFM4.58-60 However, the value of these genes as 
reliable predictors for disease outcome remains to be elucidated.
Gene pathway enrichment revealed downregulation of 
several TLRs in the remission samples (Fig. 4B). It has been 
suggested that UC may be associated with specific alterations 
in selective TLR expression in the intestinal epithelium.61, 62 
A recent report also implies a role for mucin and TLRs in pa-
tient defense against intestinal parasites.42 In this study, TLRs 
were expressed higher in normal mucosa and active UC sam-
ples than in the remission samples. These observations are most 
likely a result of different treatment strategies applied for this 
patient group and may be used to establish therapeutic options 
for UC to obtain better clinical outcomes.63-65 
A limitation of this work is the amount of patient sam-
ples, with n = 14. The low sample size made it difficult to define 
molecular remission patterns caused by different treatments. 
However the number of patients  included in this study is still 
larger than reported for other studies, and PCA (Fig.  1) re-
vealed sufficient separation of the different patient groups.21 It 
is also possible that the remission signature seen here reflects 
a response to treatment or natural recovery after initial di-
sease presentation. Such a response could have been evaluated 
FIGURE 5. Estimation of cell fractions in patient samples using the Bioconductor CellMix package and the IRIS marker set as described in “Methods.” 
The blue dots indicate normal control samples, the red dots indicate active UC samples from a former study,24 and the green dots indicate UC in re-
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with follow-up for active UC samples, which was not available 
during this study.
CONCLUSIONS
The data demonstrate that remission is a permanently al-
tered state of UC characterized by a unique transcriptional sig-
nature in the mucosa, which is different from that in UC and 
normal samples. The analysis revealed new and more specific 
molecular signatures for UC in remission compared with earlier 
studies conducted with microarrays.19-21 Partial restoration of the 
epithelial mucus layer and revival of immunological functions in 
the mucus layer were supported by the expression of protective 
genes. In addition, a clear role for bacterial gut flora composi-
tion can be implied. Some expressed genes have been associated 
with the development of colorectal cancer, but a role for these 
genes as reliable predictors for disease outcome remains uncer-
tain. Further studies will tell whether transcriptomic, epigenetic, 
metagenomic, and meta-transcriptomic signatures together can 
reveal biomarkers and/or biomarker groups of valuable character 
to be used for the prognosis of relapse and for the definition of 
new criteria for de-escalating treatment.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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